Skip to content
The Policy VaultThe Policy Vault

Eysuvis (loteprednol etabonate 0.25% ophthalmic suspension) — Medica

Dry eye disease (short-term treatment)

Initial criteria

  • Patient has tried artificial tears

Approval duration

1 month